Inhibition of PI3K by PX-866 Prevents Transforming Growth Factor-{alpha}-Induced Pulmonary Fibrosis.
The American journal of pathology 2009 Dec 30; In press
Le Cras T TD, Korfhagen T TR, Davidson C, Schmidt S, Fenchel M, Ikegami M, Whitsett J JA, Hardie W WD
From the Divisions of Pulmonary Biology* and Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Transforming growth factor-alpha (TGFalpha) is a ligand for the epidermal growth factor receptor (EGFR). EGFR activation is associated with fibroproliferative processes in human lung disease and animal models of pulmonary fibrosis. EGFR signaling activates several intracellular signaling pathways including phosphatidylinositol 3'-kinase (PI3K). We previously showed that induction of lung-specific TGFalpha expression in transgenic mice caused progressive pulmonary fibrosis over a 4-week period. The increase in levels of phosphorylated Akt, detected after 1 day of doxycycline-induced TGFalpha expression, was blocked by treatment with the PI3K inhibitor, PX-866. Daily administration of PX-866 during TGFalpha induction prevented increases in lung collagen and airway resistance as well as decreases in lung compliance. Treatment of mice with oral PX-866 4 weeks after the induction of TGFalpha prevented additional weight loss and further increases in total collagen, and attenuated changes in pulmonary mechanics. These data show that PI3K is activated in TGFalpha/EGFR-mediated pulmonary fibrosis and support further studies to determine the role of PI3K activation in human lung fibrotic disease, which could be amenable to targeted therapy.
Keywords: PX-866 Transforming growth factor-alpha TGFalpha epidermal growth factor receptor EGFR Pulmonary Fibrosis